Barings Corporate Investors (MCI) Competitors

Barings Corporate Investors (NYSE:MCI) and Abrdn Life Sciences Investors (NYSE:HQL) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends.

Is MCI or HQL a better dividend stock?

Barings Corporate Investors pays an annual dividend of $1.42 per share and has a dividend yield of 8.1%. Abrdn Life Sciences Investors pays an annual dividend of $1.33 per share and has a dividend yield of 9.4%.

Which has more risk & volatility, MCI or HQL?

Barings Corporate Investors has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Abrdn Life Sciences Investors has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Do analysts recommend MCI or HQL?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barings Corporate Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Abrdn Life Sciences Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do institutionals and insiders believe in MCI or HQL?

32.2% of Abrdn Life Sciences Investors shares are owned by institutional investors. 1.1% of Barings Corporate Investors shares are owned by insiders. Comparatively, 10.1% of Abrdn Life Sciences Investors shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer MCI or HQL?

In the previous week, Abrdn Life Sciences Investors had 5 more articles in the media than Barings Corporate Investors. MarketBeat recorded 10 mentions for Abrdn Life Sciences Investors and 5 mentions for Barings Corporate Investors. Abrdn Life Sciences Investors' average media sentiment score of 1.61 beat Barings Corporate Investors' score of 0.82 indicating that Abrdn Life Sciences Investors is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Barings Corporate Investors	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abrdn Life Sciences Investors	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is MCI or HQL more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Barings Corporate Investors	N/A	N/A	N/A
Abrdn Life Sciences Investors	N/A	N/A	N/A

Which has preferable valuation and earnings, MCI or HQL?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barings Corporate Investors	N/A	N/A	N/A	N/A	N/A
Abrdn Life Sciences Investors	N/A	N/A	N/A	N/A	N/A

Does the MarketBeat Community prefer MCI or HQL?

Barings Corporate Investors received 138 more outperform votes than Abrdn Life Sciences Investors when rated by MarketBeat users. Likewise, 75.65% of users gave Barings Corporate Investors an outperform vote while only 68.35% of users gave Abrdn Life Sciences Investors an outperform vote.

Company	Underperform	Outperform
Barings Corporate Investors	Outperform Votes 233 75.65%	Underperform Votes 75 24.35%
Abrdn Life Sciences Investors	Outperform Votes 95 68.35%	Underperform Votes 44 31.65%

Summary

Abrdn Life Sciences Investors beats Barings Corporate Investors on 6 of the 8 factors compared between the two stocks.